PMN310 Alzheimer's Trial Progress
ProMIS Neurosciences Reports Positive Interim Safety and Biomarker Data for Alzheimer's Drug PMN310
Anonymous
ProMIS Neurosciences has released encouraging six-month data from its PRECISE-AD Phase 1b trial, showing that its experimental Alzheimer's drug PMN310 is safe and producing early positive signals in disease-related biomarkers, according to Montreal Gazette. The trial enrolled 136 patients with Alzheimer's disease, and the interim results suggest the drug could represent a meaningful advance in treating the condition.
The data showed zero cases of amyloid-related imaging abnormalities-edema — a serious side effect, often called ARIA-E, that has troubled rival Alzheimer's drugs. Full 12-month results are expected in the first quarter of 2027, Ottawa Sun reported.
PMN310 Shows Clean Safety Profile Across All Patient Groups
The six-month interim analysis covered 136 Alzheimer's patients across different genetic profiles, according to Toronto Sun. PMN310 showed a favorable safety profile in every group tested. No patients developed ARIA-E, which is brain swelling caused by amyloid-clearing drugs. This side effect has been a major problem for other Alzheimer's treatments, including lecanemab and donanemab.
ARIA-E can cause headaches, confusion, and in serious cases, dangerous brain swelling. The fact that no patients developed it across all genotypes — including those carrying the APOE4 gene, which raises ARIA risk — is a notable safety finding, Stratford Beacon Herald reported.
Early Biomarker Signals Point in the Right Direction
Beyond safety, the trial showed early movement in disease-relevant biomarkers. These are measurable biological signs that track how Alzheimer's disease is progressing. The changes were described as directionally consistent, meaning they moved in the way researchers hoped, according to Financial Post.
PMN310 is designed to selectively target toxic misfolded proteins. In Alzheimer's, these proteins — including amyloid and tau — clump together and damage brain cells. Unlike some drugs that broadly clear amyloid, PMN310 aims to hit only the harmful forms, Whitecourt Star noted.
What Makes PMN310 Different From Other Alzheimer's Drugs
Most approved Alzheimer's drugs target amyloid broadly. That approach clears harmful plaques but also affects healthy tissue, which is why ARIA-E occurs. PMN310 uses a selective targeting approach, going after misfolded proteins specifically, Goderich Signal Star reported. The company believes this precision reduces the risk of damaging side effects.
ProMIS is a clinical-stage biopharmaceutical company, meaning it has not yet brought a drug to market. PMN310 is its lead candidate. The positive interim data add credibility to its approach, though the trial is still blinded — meaning researchers do not yet know which patients received the drug versus a placebo, according to The Whig.
12-Month Topline Results Due in Early 2027
The PRECISE-AD trial is still ongoing. ProMIS expects to release full 12-month topline results in the first quarter of 2027. Those results will carry far more weight than the interim data, since they will include unblinded efficacy outcomes, according to Fort Saskatchewan Record.
Alzheimer's disease affects tens of millions of people worldwide. Only a handful of drugs have ever shown the ability to slow its progression. If PMN310 performs well at 12 months, it could move into larger Phase 2 or Phase 3 trials. For now, the six-month safety data give the company a clear path to continue, Ottawa Sun reported.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
9
Articles
9
Reach
9
A
AnonymousAuthor
